Gyre Therapeutics, Inc
Price
FilingsNewest: Form 10-Q, quarterly reportNov 5 →InsidersNo open-market buys. 2 insiders sold $952,874, 2 of 18 sales on a 10b5-1 plan.→Financing →PeersClosest companies: BYSI, ORIC, ONC→
From the filings
Figures
- Revenue
- $121.8Mlast 12 months
- Net income
- −$36.6Mlast 12 months
- Operating cash flow
- −$4.9Mlast 12 months
- Cash and equivalents
- $41.6Mat the last balance sheet
- Shares outstanding
- 107.1M shareson issue
Filings, newest first
- Nov 510-QQuarterly report
- Nov 58-KResults of operations
- Oct 228-KDirector or officer change
- Sep 18-KRegulation FD disclosure
- Aug 268-KRegulation FD disclosure
- Aug 710-QQuarterly report
- Aug 78-KResults of operations
- Jul 168-KDirector or officer change
- Jun 224Insider trade
- Jun 154Insider trade
- Mar 1310-KAnnual report